| P2093 | author name string | Kermit L Carraway | |
| | Colleen Sweeney | |
| | Lakmal Kotelawala | |
| | William H D Fry | |
| P2860 | cites work | A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4 | Q24291286 |
| | An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels | Q24292374 |
| | Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8 | Q24301536 |
| | Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface | Q24301761 |
| | The ubiquitin isopeptidase UBPY regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation | Q24306674 |
| | Characterization of human LNX, a novel ligand of Numb protein X that is downregulated in human gliomas | Q24307298 |
| | Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling | Q24321251 |
| | Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth | Q24322731 |
| | LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation | Q24536102 |
| | Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3 | Q24538330 |
| | Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype. | Q24539106 |
| | Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain | Q24551173 |
| | Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype | Q24561448 |
| | LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation | Q24563349 |
| | v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas | Q24624849 |
| | LNX1 is a perisynaptic Schwann cell specific E3 ubiquitin ligase that interacts with ErbB2. | Q48790954 |
| | Argos mutants define an affinity threshold for spitz inhibition in vivo. | Q52011453 |
| | Evidence that Argos is an antagonistic ligand of the EGF receptor. | Q52581255 |
| | Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 |
| | Therapeutic potential of epidermal growth factor receptor-related protein | Q79377442 |
| | Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 |
| | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 |
| | Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1 | Q24681497 |
| | The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 |
| | Structural basis for EGFR ligand sequestration by Argos | Q27650677 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Untangling the ErbB signalling network | Q27860884 |
| | The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor | Q28118420 |
| | Feedback inhibition by RALT controls signal output by the ErbB network | Q28183228 |
| | Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope | Q28213528 |
| | Evidence that MIG-6 is a tumor-suppressor gene | Q28250282 |
| | Argos inhibits epidermal growth factor receptor signalling by ligand sequestration | Q28278895 |
| | Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease | Q28570541 |
| | Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation | Q28590384 |
| | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 |
| | Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 | Q29617290 |
| | c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor | Q29618661 |
| | The emerging shape of the ESCRT machinery | Q29620787 |
| | Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation | Q29622825 |
| | Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation | Q30159469 |
| | Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin | Q30839490 |
| | Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study | Q33377626 |
| | Negative feedback mechanisms and their roles during pattern formation | Q33591813 |
| | ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 |
| | Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer | Q33890758 |
| | Cloning, characterization, and expression of human LIG1. | Q33952106 |
| | A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling | Q34085603 |
| | Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor | Q34088545 |
| | Feedback control of intercellular signalling in development | Q34094396 |
| | Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest | Q34122281 |
| | Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia | Q34133670 |
| | Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? | Q34149663 |
| | HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms | Q34183239 |
| | LRIG1 protein in human cells and tissues | Q34189486 |
| | Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu | Q34190181 |
| | Inhibitors of cytokine signal transduction | Q34275568 |
| | Inhibition of Drosophila EGF receptor activation by the secreted protein Argos. | Q34303458 |
| | The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases | Q34345557 |
| | ErbB receptors: new insights on mechanisms and biology | Q34579265 |
| | Knockouts of Kekkon1 define sequence elements essential for Drosophila epidermal growth factor receptor inhibition | Q34643376 |
| | Bipartite inhibition of Drosophila epidermal growth factor receptor by the extracellular and transmembrane domains of Kekkon1. | Q34644725 |
| | Trafficking of the ErbB receptors and its influence on signaling | Q35089318 |
| | The ErbB receptors and their role in cancer progression. | Q35089324 |
| | Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases | Q35169572 |
| | Heat shock protein 90. | Q35587293 |
| | ErbB receptors: directing key signaling networks throughout life | Q35639126 |
| | Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity | Q35641650 |
| | Signal transduction and oncogenesis by ErbB/HER receptors | Q35669114 |
| | The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response | Q35698515 |
| | Expression of the ERBB3 gene product in breast cancer | Q35994633 |
| | EGF receptor ubiquitination is not necessary for its internalization | Q36089385 |
| | Expression of c-erbB3 protein in primary breast carcinomas | Q36115645 |
| | Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis | Q36328720 |
| | Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 |
| | Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer | Q37003688 |
| | Association with membrane protrusions makes ErbB2 an internalization-resistant receptor | Q38345553 |
| | Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation | Q38669920 |
| | The interaction between the Drosophila secreted protein argos and the epidermal growth factor receptor inhibits dimerization of the receptor and binding of secreted spitz to the receptor | Q39584855 |
| | The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane | Q39848000 |
| | Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: an autoinhibition mechanism of ErbB2 expression | Q40318540 |
| | Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis | Q40402570 |
| | Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells | Q40446727 |
| | Decorin prevents metastatic spreading of breast cancer. | Q40462238 |
| | Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. | Q40465340 |
| | Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR. | Q40815002 |
| | Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention | Q41472786 |
| | Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation | Q42466638 |
| | A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity | Q42498384 |
| | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 |
| | All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired | Q42816057 |
| | Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. | Q44010445 |
| | Endocytosis of Receptor Tyrosine Kinases Is Driven by Monoubiquitylation, Not Polyubiquitylation | Q44420471 |
| | Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 |
| | Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1. | Q44538281 |
| | Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2 | Q44645808 |
| | Neuregulin-induced expression of the acetylcholine receptor requires endocytosis of ErbB receptors | Q45251213 |
| | The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. | Q47070283 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 697-706 | |
| P577 | publication date | 2008-07-31 | |
| P1433 | published in | Experimental Cell Research | Q1524289 |
| P1476 | title | Mechanisms of ErbB receptor negative regulation and relevance in cancer | |
| P478 | volume | 315 | |